Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Autologous CD34+ Hematopoietic Stem Cells Transduced ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Lentiviral Vector Encoding for the Human ADA Gene

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01852071
Recruitment Status : Completed
First Posted : May 13, 2013
Results First Posted : September 20, 2021
Last Update Posted : September 20, 2021
Sponsor:
Collaborators:
National Institute of Allergy and Infectious Diseases (NIAID)
National Human Genome Research Institute (NHGRI)
National Heart, Lung, and Blood Institute (NHLBI)
University of California, Los Angeles
Information provided by (Responsible Party):
Orchard Therapeutics

Brief Summary:
The aim of this study is to assess the safety and efficacy of autologous transplantation of hematopoietic stem cells (CD34+ cells) from the bone marrow (BM) of ADA-deficient SCID infants and children following human ADA cDNA transfer by the EFS-ADA lentiviral vector. The level of gene transfer in blood cells and immune function will be measured as endpoints.

Condition or disease Intervention/treatment Phase
ADA-SCID Genetic: Infusion of autologous EFS-ADA LV CD34+ (OTL-101) Drug: busulfan Drug: PEG-ADA ERT Phase 1 Phase 2

Detailed Description:
The study is open to twenty (20) infants and children diagnosed with ADA-deficient SCID who did not have a medically eligible, human leukocyte antigen (HLA)-identical sibling donor for bone marrow transplantation. The EFS-ADA lentiviral vector with the human ADA cDNA will be used to transduce autologous CD34+ cells from the bone marrow of these subjects. The subjects will receive 4 mg/kg busulfan prior to re-infusion of their gene-modified cells. Safety is the primary endpoint. During the follow-up phase, the investigators aim to determine whether the cells could engraft and produce mature cells that contain and express the corrected ADA gene in the absence of pegademase bovine (PEG-ADA) enzyme replacement therapy (ERT), which will be withheld at Day +30 following transplant. Efficacy studies to evaluate the level of immune reconstitution, will be performed in the first and second years of the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 46 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Autologous Transplantation of Bone Marrow CD34+ Stem/Progenitor Cells After Addition of a Normal Human ADA Complementary DNA (cDNA) by the EFS-ADA Lentiviral Vector for Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency (ADA-SCID)
Actual Study Start Date : August 2, 2013
Actual Primary Completion Date : August 27, 2018
Actual Study Completion Date : August 27, 2018


Arm Intervention/treatment
Experimental: Gene Therapy
Infusion of autologous EFS-ADA Lentiviral (LV) CD34+ cells
Genetic: Infusion of autologous EFS-ADA LV CD34+ (OTL-101)
autologous EFS-ADA LV CD34+ cells (OTL-101) are infused intravenously
Other Name: OTL-101

Drug: busulfan
Busulfan is used for non-myeloablative conditioning

Drug: PEG-ADA ERT
PEG-ADA ERT is discontinued at Day +30 (-3/+15 days) after successful engraftment




Primary Outcome Measures :
  1. Overall Survival (OS) of Subjects Treated With Investigational Medicinal Product (IMP) (1 Year) [ Time Frame: 12 months ]
    Overall survival is defined as the percentage of subjects alive at 12 months post- treatment with OTL-101 or HSCT

  2. Event-free Survival (EvFS) of Subjects Treated With Investigational Medicinal Product (IMP) (1 Year) [ Time Frame: 12 months ]
    Event-free survival is defined as the percentage of subjects alive with no "event", an "event" being the resumption of PEG-ADA ERT or the need for a rescue allogeneic Hematopoietic Stem Cell Transplant (HSCT), or death.


Secondary Outcome Measures :
  1. OS of Subjects Treated With Investigational Medicinal Product (IMP) (2 Years) [ Time Frame: 24 months ]
    OS is defined as the percentage of subjects alive at 24 months post- treatment with OTL-101 or HSCT

  2. EvFS of Subjects Treated With Investigational Medicinal Product (IMP) (2 Years) [ Time Frame: 24 months ]
    Event-free survival is defined as the percentage of subjects alive with no "event", an "event" being the resumption of PEG-ADA ERT or the need for a rescue allogenic Hematopoietic Stem Cell Transplant (HSCT), or death.

  3. Vector Copy Number (VCN) in Peripheral Blood (PB) Granulocytes. [ Time Frame: 24 months ]
    Vector copy number in the PB granulocyte fraction that was T cell depleted, is a surrogate for amount of engrafted genetically modified Hematopoietic stem cell (HSC) that are producing granulocytes every 3-5 days. VCN analysis was performed by Droplet Digital PCR (ddPCR) on DNA extracted from peripheral blood granulocytes.

  4. VCN in Peripheral Blood Mononuclear Cells (PBMCs) [ Time Frame: 24 months ]
    PBMC VCN is a measure of the accumulation of peripheral blood leukocytes arising from engrafted, genetically modified HSC. VCN analysis was performed by ddPCR on DNA extracted from PBMC.

  5. ADA Activity in Erythrocytes [ Time Frame: 24 months ]
    ADA enzyme activity measured to assess the amount of functional gene product produced from the normal ADA transgene delivered by EFS-ADA LV; persistence of ADA enzyme activity over time demonstrates successful engraftment and differentiation of genetically modified HSC.

  6. Reduction in Deoxyadenosine Nucleotide (dAXP) in Erythrocytes [ Time Frame: 24 months ]
    Decreased dAXP levels coincide with increased ADA enzyme activity, detoxification was used to demonstrate functional ADA enzyme production from the introduced ADA transgene. The threshold for detoxification was <100 μmol/L.

  7. Change From Baseline in CD3+ T Cell Counts (2 Years) [ Time Frame: 24 months ]
    Immune reconstitution was assessed by change in CD3+ T Cell counts over time.

  8. Number of Single Integration Sites Representing >30% of the Total Integration Sites (2 Years) [ Time Frame: 24 months ]
    Vector Integration Site Analysis (VISA) allowed determination of the distribution of vector integration sites in each subject's genome, as well as the relative clonal abundance. VISA was to be considered abnormal for a subject if, in 2 or more instances during the course of follow-up, a single integration site was found to represent >30% of the total integration sites detected.

  9. Severe Infection Rate Excluding the First Three Months After Treatment [ Time Frame: 24 months ]
    The infections of interest in this study were severe infections or opportunistic infectious episodes, defined as infections requiring hospitalization or prolonging hospitalization and/or documented infections by opportunistic pathogens. Infections that took place in the first 3 months of follow-up post treatment were excluded from calculations to avoid possible bias introduced in the data by the effects of conditioning.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Month to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

-Children ≥ 1.0 months of age with a diagnosis of ADA-deficient SCID based on A. Decreased ADA enzymatic activity in erythrocytes, leukocytes, skin fibroblasts, or in cultured fetal cells to levels consistent with ADA-deficient SCID as determined by reference laboratory or confirmed ADA gene mutation(s) known to cause disease , AND

B. Evidence of severe combined immunodeficiency based on either:

  1. Family history of first order relative with ADA deficiency and clinical and laboratory evidence of severe immunologic deficiency, OR
  2. Evidence of severe immunologic deficiency in subject prior to institution of immune restorative therapy, based on

    1. lymphopenia (absolute lymphocyte count <400 cells/mcL) OR absence or low number of T cells (absolute CD3+ count <300 cells/mcL) OR
    2. severely decreased T lymphocyte blastogenic responses to phytohemagglutinin (either <10% of lower limit of normal controls for the diagnostic laboratory, <10% of the response of the normal control of the day, or stimulation index <10)

      • Ineligible for matched sibling allogeneic bone marrow transplantation: absence of a medically eligible HLA-identical sibling, with normal immune function, who may serve as an allogeneic bone marrow donor
      • Signed written informed consent according to guidelines of the Institutional Review Board (IRB) (UCLA Office of Human Research Protection Program and National Human Genome Research Institute (NHGRI) IRB

Exclusion Criteria:

  1. Age ≤ 1.0 months Appropriate organ function as outlined below must be observed within 60 days of entering this trial.
  2. Hematologic

    1. Anemia (hemoglobin < 10.5 g/dl at < 2 years of age, or < 11.5 g/dl at > 2 years of age).
    2. Neutropenia (absolute granulocyte count <500/mm3.
    3. Thrombocytopenia (platelet count < 150,000/mm3, at any age).
    4. International Normalised Ratio (INR) or Prothrombin Time (PT) > 2 times the upper limits of normal or Partial Thromboplastin Time (PTT) > 2.33 times the upper limit of normal (patients with a correctable deficiency controlled on medication will not be excluded).
    5. Cytogenetic abnormalities on peripheral blood or bone marrow or amniotic fluid (if available).
    6. Prior allogeneic Hematopoietic Stem Cell Transplant (HSCT) with cytoreductive conditioning
  3. Infectious

    a. Evidence of infection with HIV-1, hepatitis B, Hepatitis C, or parvovirus B 19 by DNA Polymerase Chain Reaction (PCR) within 90 days prior to bone marrow harvest. If other infection is present, it must be under control (e.g. stable or decreasing viral load) at the time of screening

  4. Pulmonary

    1. Resting O2 saturation by pulse oximetry < 95% on room air.
    2. Chest x-ray indicating active or progressive pulmonary disease.
  5. Cardiac

    1. Abnormal electrocardiogram (EKG) indicating cardiac pathology.
    2. Uncorrected congenital cardiac malformation with clinical symptomatology.
    3. Active cardiac disease, including clinical evidence of congestive heart failure, cyanosis, hypotension.
    4. Poor cardiac function as evidenced by LV ejection fraction < 40% on echocardiogram.
  6. Neurologic

    1. Significant neurologic abnormality by examination.
    2. Uncontrolled seizure disorder.
  7. Renal

    1. Renal insufficiency: serum creatinine >= 1.2 mg/dl, or >= 3+ proteinuria.
    2. Abnormal serum sodium, potassium, calcium, magnesium, phosphate at grade III or IV by Division of AIDS Toxicity Scale.
  8. Hepatic/GI:

    1. Serum transaminases > 5 times the upper limit of normal (ULN).
    2. Serum bilirubin > 2 times ULN.
    3. Serum glucose > 1.5 times ULN.
    4. Intractable severe diarrhea.
  9. Oncologic

    1. Evidence of active malignant disease other than dermatofibrosarcoma protuberans (DFSP)
    2. Evidence of DFSP expected to require anti-neoplastic therapy within the 5 years following the infusion of genetically corrected cells
    3. Evidence of DFSP expected to be life limiting within the 5 years following the infusion of genetically corrected cells
  10. Known sensitivity to Busulfan
  11. General

    1. Expected survival < 6 months.
    2. Pregnant.
    3. Major congenital anomaly.
    4. Ineligible for autologous HSCT by the criteria at the clinical site.
    5. Other conditions which in the opinion of the principal investigator and/or co-investigators, contra-indicate the bone marrow harvest, the administration of busulfan, infusion of transduced cells or indicate the patient or patient's parents/primary caregivers inability to follow protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01852071


Locations
Layout table for location information
United States, California
Mattel Children's Hospital, UCLA
Los Angeles, California, United States, 90095
United States, Maryland
Mark O. Hatfield Clinical Research Center, NIH
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
Orchard Therapeutics
National Institute of Allergy and Infectious Diseases (NIAID)
National Human Genome Research Institute (NHGRI)
National Heart, Lung, and Blood Institute (NHLBI)
University of California, Los Angeles
Investigators
Layout table for investigator information
Principal Investigator: Donald B Kohn, MD University of California, Los Angeles
  Study Documents (Full-Text)

Documents provided by Orchard Therapeutics:
Study Protocol  [PDF] March 28, 2018
Statistical Analysis Plan  [PDF] October 24, 2017

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Orchard Therapeutics
ClinicalTrials.gov Identifier: NCT01852071    
Other Study ID Numbers: EFS-ADA
U01AI100801 ( U.S. NIH Grant/Contract )
2P01HL073104 ( U.S. NIH Grant/Contract )
0910-1006 ( Other Identifier: OBA-RAC )
First Posted: May 13, 2013    Key Record Dates
Results First Posted: September 20, 2021
Last Update Posted: September 20, 2021
Last Verified: August 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Keywords provided by Orchard Therapeutics:
gene therapy
hematopoietic stem cell
ADA-SCID
lentiviral vector
Additional relevant MeSH terms:
Layout table for MeSH terms
Busulfan
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents, Alkylating
Antineoplastic Agents
Myeloablative Agonists